Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Prasugrel-related hepatotoxicity
View through CrossRef
Prasugrel is usually preferred over Clopidogrel to reduce the risk of recurrent coronary thrombosis in patients who undergo percutaneous coronary interventions during an acute coronary syndrome owing to its more potent and more rapid antithrombotic activation. Little is known about Prasugrel-induced hepatotoxicity, although mild-to-moderate alanine transaminase (ALT) and gamma glutamyl transpeptidase (GGT) elevations have been noticed in post-marketing surveillance. Herein, we report the case of a patient with Prasugrel-related hepatotoxicity that was reverted after switching from Prasugrel to Ticagrelor.
Keywords: Percutanous coronary interventions, antiplatelet drug, Prasugrel, hepatotoxicity.
Pakistan Medical Association
Title: Prasugrel-related hepatotoxicity
Description:
Prasugrel is usually preferred over Clopidogrel to reduce the risk of recurrent coronary thrombosis in patients who undergo percutaneous coronary interventions during an acute coronary syndrome owing to its more potent and more rapid antithrombotic activation.
Little is known about Prasugrel-induced hepatotoxicity, although mild-to-moderate alanine transaminase (ALT) and gamma glutamyl transpeptidase (GGT) elevations have been noticed in post-marketing surveillance.
Herein, we report the case of a patient with Prasugrel-related hepatotoxicity that was reverted after switching from Prasugrel to Ticagrelor.
Keywords: Percutanous coronary interventions, antiplatelet drug, Prasugrel, hepatotoxicity.
Related Results
Post-procedural high platelet reactivity with prasugrel loading predicts in-hospital adverse events in ACS patients
Post-procedural high platelet reactivity with prasugrel loading predicts in-hospital adverse events in ACS patients
Abstract
Background/Introduction
High platelet reactivity (HPR) is associated with adverse cardiovascular events, primarily intr...
Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
Background: East Asian patients receiving treatment with the potent P2Y12 inhibitors prasugrel or ticagrelor experience more potent platelet inhibition than with clopidogrel. Metho...
Comparative efficacy and safety of ticagrelor vs. prasugrel in patients undergoing PCI for NSTE-ACS. Results of the prospective ALKK-Registry
Comparative efficacy and safety of ticagrelor vs. prasugrel in patients undergoing PCI for NSTE-ACS. Results of the prospective ALKK-Registry
Abstract
Background
Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor has become standard of care for patients with N...
Ticagrelor or prasugrel versus clopidogrel in patients with coronary heart disease
Ticagrelor or prasugrel versus clopidogrel in patients with coronary heart disease
Abstract
Introduction
Antiplatelet therapy is pivotal in the management of coronary heart disease (CHD), especially after percut...
GW24-e2375 Onset of antiplatelet effect of prasugrel and ticagrelor is delayed in patients with acute coronary syndromes
GW24-e2375 Onset of antiplatelet effect of prasugrel and ticagrelor is delayed in patients with acute coronary syndromes
Objectives
A more rapid onset of antiplatelet effect following loading with prasugrel and ticagrelor compared to clopidogrel was demonstrated for healthy subjects...
P4634Acute-phase high platelet reactivity with prasugrel loading is correlated with clinical outcomes during hospitalization in acute coronary syndrome
P4634Acute-phase high platelet reactivity with prasugrel loading is correlated with clinical outcomes during hospitalization in acute coronary syndrome
Abstract
Background/Introduction
Although high platelet reactivity (HPR) seems to be associated with adverse cardiovascular even...
Case Reports on Severe Antituberculosis-Drug Induced Hepatotoxicity in Tuberculosis Patients: The Post-Incidence Therapy
Case Reports on Severe Antituberculosis-Drug Induced Hepatotoxicity in Tuberculosis Patients: The Post-Incidence Therapy
Introduction: The first-line regimen for tuberculosis (TB) treatment comprises Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol. However, these drugs are known to potentially c...
Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade
Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade
Summary. The aim of the study was to assess the incidence and the cumulative probability of cytolytic and cholestatic hepatotoxicity during antiretroviral treatment in a group of ...